the company informs us of an update of what had already been...

the company informs us of an update of what had already been established. in all likelihood, the main intention is to confirm times and dynamics in such a way as to mitigate the level of uncertainty, which for some time has conditioned the behavior of the stock on the market.there is no doubt that in the coming months Neuren will attract the attention of investors. what is increasingly evident and which convinces more and more to maintain the position on the title is that in the short and medium term, there will be a convergence towards a single key point, given the fact that 2591 will advance in phase 2 and trofinetide will shorten in the times of response to phase 3. everything seems to be scheduled for October / November next year. in the meantime the market will necessarily have to discount this eventuality and for reasons of cause and intrinsic value presumed to date, the price on the market will first intercept the conversion price of $ 1.84, in conjunction with the opening of phase 2 for 2591 contemporaneity of the orphan designation in Europe next January. secondly, during the first half of 2021 it will be structured to discount the good things there will be in the second half of the year. in numerical and technical terms, this corresponds to the price levels recorded in the period preceding the agreement with acadia, or the technical threshold of $ 3.I think this forecast is realistic, with the addition that the real turning point capable of splitting the market equilibrium is naturally linked to a large amount of incoming money, which can be generated either for a partnership for 2591 opening or in progress phase 2, or for acadia initiatives following opportunistic evaluations dictated by the interest above all for the vaucher.

all in all, it is still and despite everything, to continue to be invested in this company.